en.Wedoany.com Reported - Antag Therapeutics presented Phase 1 and preclinical data for its GIP receptor antagonist AT7687 at the 2026 American Diabetes Association (ADA) Scientific Sessions. The study showed that AT7687 was well tolerated, has the potential for once-weekly subcutaneous administration, and demonstrated evidence of target engagement at the tested doses.
This randomized, placebo-controlled Phase 1 study included 102 participants, encompassing healthy volunteers with normal weight and obesity. In both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, AT7687 exhibited good safety and tolerability, with no serious adverse events reported. Regarding key gastrointestinal tolerability, adverse events were reported as mild and were similarly distributed between the AT7687 and placebo groups, with no signals of poor gastrointestinal tolerability. Pharmacokinetic analysis showed dose-proportional exposure and low inter-subject variability, consistent with once-weekly dosing characteristics.
The company also presented new preclinical data. In an obese, insulin-resistant non-human primate (NHP) model, AT7687 in combination with cagrilintide for 42 days resulted in a 12.2% reduction in body weight from baseline, superior to the 7.8% reduction observed with cagrilintide monotherapy. Regarding insulin sensitivity, the combination group showed an 18.9% increase in the glucose disappearance rate, while the monotherapy group experienced a 1.3% decrease. The combination therapy also led to the greatest reduction in body fat percentage, and cumulative energy intake was similar between the two groups, suggesting that the enhanced weight loss may not be solely explained by appetite suppression. These data further confirm the potential metabolic benefits of AT7687 when combined with cagrilintide.
Philip Just Larsen, CEO of Antag Therapeutics, stated that these data support the potential of GIP receptor antagonism as a next-generation treatment modality for obesity and cardiometabolic diseases. Chief Medical Officer Richard Nkulikiyinka noted that AT7687 exhibits a favorable gastrointestinal tolerability profile and requires no titration, showing promising characteristics both as a monotherapy and in combination with other therapies. Based on these findings, the company expects to initiate a Phase 2a study of AT7687 in mid-2026.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
